China's traditional Chinese medicine industry is facing "malaise" 
 
 
August 18, 2014 10:59 business club
 
 
August 18 - business club 

        In spite of 2013 years of Chinese medicines, Chinese herbal medicine yinpian processing and manufacturing industry's main income rose more than 20%, but in jilin dunhua 16 end of the second China yanbian medical health industry development peak BBS, "capital linkage, innovation and development" and "transform" remains China's nine with the highest frequency is "top" of traditional Chinese medicine experts keywords. 
 
 
        Since 1992 the state council promulgated the regulations on the protection of TCM variety, traditional Chinese medicine (TCM) industry as an important part of medicine health industry with Chinese characteristics is widely attention: large varieties of traditional Chinese medicines with annual sales of more than RMB 100 million in 1994 from two rapid expansion in 2012 to 350. In the global pharmaceuticals market into the low speed growth range, traditional Chinese medicine (TCM) industry in China still dominate. 
 
 
        But analysis, according to a report from the ministry because affected by the large scale of investment in fixed assets in recent years, Chinese medicine enterprise cost is rising; API is difficult to cut capacity for short periods of time, most of the products is expected to get the price low; In addition, due to the year of 2014 drug bidding procurement is relatively dense, the bidding procurement prices continue to decline trend; Some of the eastern province of the development of enterprises, but also is under the constraints of environment and resources and the test. 
 
 
        Chinese medicine experts, have a headache not only have a "home", more "foreign" : because the raw material source, pharmacodynamic mechanism, target principle aspects such as lack of evidence-based basis for a long time, increased the difficulty of China's traditional Chinese medicine to world. 
 
 
        At present, China has not been one therapeutic drug approved by the us food and drug administration (fda); Britain also has from the beginning of the year in the comprehensive bans on traditional Chinese medicine (TCM); The world health organization has reported that even "Chinese exports of traditional Chinese medicines of the world's only 3% to 5%, as close neighbors South Korea and Japan". 
 
 
        "People think Chinese traditional medicine industry transformation is not so much" for a rainy day ", rather than a 'QiongJiSiBian." China association of traditional Chinese medicine drugs, said huang min, deputy secretary-general of the clinical evaluation research branch of once the present health care payment according to macro-reforms, according to medicare payments pricing, third-party payment and other trends, then some can't find the corresponding disease of traditional Chinese medicine yinpian, injection price wave will surely, if the majority of Chinese medicine major varieties are not into the future of health care in China, the Chinese medicine industry will soon usher in "life and death moment". 
 
 
        Since 2013, Chinese herbal medicine industry is quietly changing, in order to improve the efficiency of resource allocation, active pharmaceutical industry merger and reorganization, "many advantages to enterprises mergers and reorganization as the important way to become bigger and stronger, in particular, some listed companies through the capital market financing function, fast growth, through mergers and acquisitions." China pharmaceutical industry association (12.58, 0.16, 1.29%), vice President of Duan Jidong said. 
 
        According to incomplete statistics, in 2013, a total of mergers and acquisitions between China's domestic drug firms more than 150, transaction value of 35 billion yuan of above. 
 
 
        Except through the merger and reorganization to improve enterprise product structure, for the market sales, higher clinical value and market value, large varieties of traditional Chinese medicines to realize the "secondary development" also become the guide of TCM industry innovation development of another important strategy. 
 
 
        In tianjin, several modern Chinese medicine research and development production related technology platform have established, its comprehensive strength has grown for TCM modernization; In the 2790 kinds of medicinal biological resources with medicine "in jilin province, its research has invested 166 million yuan, drive the enterprise investment 1.95 billion yuan, support 64 medicine big varieties in secondary development. In 2013, the 64 varieties sales output value of nearly 20 billion yuan, the input-output ratio of 1:9. 
 
 
        "Compared with the developed countries, China's pharmaceutical industry accounted for the proportion of the national economy and capital market has much room to improve. China has several similar to changbai mountain natural medicine treasure, good resources advantage is the key to do a good job in industry. We" Secretary general of the China association of traditional Chinese medicine wang said.
 
 
(source: xinhua)